When analysis was limited to CHIP variants in CLL-related genes (CHIP-CLL), individuals with both CHIP-CLL and MBL (N = 45) had a 20.93-fold increased risk of lymphoid malignancies (95% CI: 8.24–53.19, P < 0.001, Supplementary Fig. 3) compared to the 3.31-fold risk among individuals with MBL alone (95% CI: 2.10–5.20, P < 0.001) and the 3.62-fold risk among individuals with CHIP-CLL alone (95% CI: 1.31–10.06, P = 0.014). This evidence concerns the gene STUB1 and B-cell chronic lymphocytic leukemia.